Soligenix, Inc.

NasdaqCM:SNGX Stock Report

Market Cap: US$7.4m

Soligenix Management

Management criteria checks 4/4

Soligenix's CEO is Christopher Schaber, appointed in Aug 2006, has a tenure of 18.33 years. total yearly compensation is $700.49K, comprised of 74.2% salary and 25.8% bonuses, including company stock and options. directly owns 0.015% of the company’s shares, worth $1.12K. The average tenure of the management team and the board of directors is 10.5 years and 15.5 years respectively.

Key information

Christopher Schaber

Chief executive officer

US$700.5k

Total compensation

CEO salary percentage74.2%
CEO tenure18.3yrs
CEO ownership0.02%
Management average tenure10.5yrs
Board average tenure15.5yrs

Recent management updates

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Sep 06

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Aug 12

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Jul 25

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Apr 22
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Jan 03
Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17
Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30
Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08
Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16
What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

CEO Compensation Analysis

How has Christopher Schaber's remuneration changed compared to Soligenix's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$7m

Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$7m

Dec 31 2023US$700kUS$519k

-US$6m

Sep 30 2023n/an/a

-US$8m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$711kUS$499k

-US$14m

Sep 30 2022n/an/a

-US$15m

Jun 30 2022n/an/a

-US$15m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$687kUS$485k

-US$13m

Sep 30 2021n/an/a

-US$13m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020US$944kUS$475k

-US$18m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$15m

Dec 31 2019US$688kUS$466k

-US$9m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$619kUS$453k

-US$9m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$7m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$674kUS$444k

-US$7m

Compensation vs Market: Christopher's total compensation ($USD700.49K) is about average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Christopher's compensation has been consistent with company performance over the past year.

CEO

Christopher Schaber (58 yo)

18.3yrs

Tenure

US$700,485

Compensation

Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Schaber
Chairman of the Board of Directors18.3yrsUS$700.49k0.015%
$ 1.1k
Jonathan Guarino
Senior VP5.3yrsUS$354.69k0.0018%
$ 135.5
Oreola Donini
Senior VP & Chief Scientific Officer10yrsUS$387.59k0%
$ 0
Richard Straube
Senior VP & Chief Medical Officer10.9yrsUS$249.94k0.0014%
$ 99.9

10.5yrs

Average Tenure

55yo

Average Age

Experienced Management: SNGX's management team is seasoned and experienced (10.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Schaber
Chairman of the Board of Directors18.3yrsUS$700.49k0.015%
$ 1.1k
Jerome Zeldis
Independent Director13.5yrsUS$72.50k0.0038%
$ 283.5
Gregory Lapointe
Independent Director15.8yrsUS$77.50k0.0012%
$ 91.8
Robert Rubin
Independent Director15.2yrsUS$80.00k0.00076%
$ 56.3
Dorothy Mary Keefe
Member of Oral Mucositis Medical Advisory Boardno datano datano data
Jeffrey Hyams
Member of Pediatric Crohn's Disease Medical Advisory Boardno datano datano data
James Markowitz
Member of Pediatric Crohn's Disease Medical Advisory Boardno datano datano data
Joel Rosh
Member of Pediatric Crohn's Disease Medical Advisory Boardno datano datano data
Alain Rook
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno datano datano data
Mark Schubert
Member of Oral Mucositis Medical Advisory Boardno datano datano data
Youn Kim
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno datano datano data
Gary Wood
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno datano datano data

15.5yrs

Average Tenure

69.5yo

Average Age

Experienced Board: SNGX's board of directors are seasoned and experienced ( 15.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Soligenix, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerAegis Capital Corporation
James MolloyAlliance Global Partners
Jonathan AschoffBrean Capital